493 related articles for article (PubMed ID: 29028099)
21. Serum CA19-9 as a predictor of malignancy in primary ovarian mucinous tumors: a matched case-control study.
Cho HY; Kyung MS
Med Sci Monit; 2014 Jul; 20():1334-9. PubMed ID: 25073801
[TBL] [Abstract][Full Text] [Related]
22. [Diagnostic and prognostic value of tumor markers, scores (clinical and biological) algorithms, in front of an ovarian mass suspected of an epithelial ovarian cancer: Article drafted from the French Guidelines in oncology entitled "Initial management of patients with epithelial ovarian cancer" developed by FRANCOGYN, CNGOF, SFOG, GINECO-ARCAGY under the aegis of CNGOF and endorsed by INCa].
Bendifallah S; Body G; Daraï E; Ouldamer L
Gynecol Obstet Fertil Senol; 2019 Feb; 47(2):134-154. PubMed ID: 30733191
[TBL] [Abstract][Full Text] [Related]
23. Clinical value of CA125, CA19-9, CEA, CA72-4, and TPA in borderline ovarian tumor.
Tamakoshi K; Kikkawa F; Shibata K; Tomoda K; Obata NH; Wakahara F; Tokuhashi Y; Ishikawa H; Kawai M; Tomoda Y
Gynecol Oncol; 1996 Jul; 62(1):67-72. PubMed ID: 8690294
[TBL] [Abstract][Full Text] [Related]
24. The Value of Serum CA125 in the Diagnosis of Borderline Tumors of the Ovary: A Subanalysis of the Prospective Multicenter ROBOT Study.
Fotopoulou C; Sehouli J; Ewald-Riegler N; de Gregorio N; Reuss A; Richter R; Mahner S; Kommoss F; Schmalfeldt B; Fehm T; Hanker L; Wimberger P; Canzler U; Pfisterer J; Kommoss S; Hauptmann S; du Bois A;
Int J Gynecol Cancer; 2015 Sep; 25(7):1248-52. PubMed ID: 25978292
[TBL] [Abstract][Full Text] [Related]
25. Serum HE4 superior to CA125 in predicting poorer surgical outcome of epithelial ovarian cancer.
Shen Y; Li L
Tumour Biol; 2016 Nov; 37(11):14765-14772. PubMed ID: 27629144
[TBL] [Abstract][Full Text] [Related]
26. Applicative Value of Serum CA19-9, CEA, CA125 and CA242 in Diagnosis and Prognosis for Patients with Pancreatic Cancer Treated by Concurrent Chemoradiotherapy.
Gu YL; Lan C; Pei H; Yang SN; Liu YF; Xiao LL
Asian Pac J Cancer Prev; 2015; 16(15):6569-73. PubMed ID: 26434876
[TBL] [Abstract][Full Text] [Related]
27. Prognostic impact of prechemotherapy serum levels of HER2, CA125, and HE4 in ovarian cancer patients.
Steffensen KD; Waldstrøm M; Brandslund I; Jakobsen A
Int J Gynecol Cancer; 2011 Aug; 21(6):1040-7. PubMed ID: 21738039
[TBL] [Abstract][Full Text] [Related]
28. High levels of pretreatment CA125 are associated to improved survival in high grade serous ovarian carcinoma.
Morales-Vásquez F; Pedernera E; Reynaga-Obregón J; López-Basave HN; Gómora MJ; Carlón E; Cárdenas S; Silva-Ayala R; Almaraz M; Méndez C
J Ovarian Res; 2016 Jul; 9(1):41. PubMed ID: 27388275
[TBL] [Abstract][Full Text] [Related]
29. [Clinical validation of multiple biomarkers suspension array technology for ovarian cancer].
Zhao BB; Yang ZJ; Wang Q; Pan ZM; Zhang W; Li L
Zhonghua Fu Chan Ke Za Zhi; 2017 Jan; 52(1):11-19. PubMed ID: 28190310
[No Abstract] [Full Text] [Related]
30. [The sensitivity of the CA125 immunoradiometric assay for patients with epithelial ovarian cancer and its correlation with complex treatment].
Shi W; Zhang YJ; Jiang CY
Zhonghua Fu Chan Ke Za Zhi; 1994 Oct; 29(10):604-6, 637-8. PubMed ID: 7712875
[TBL] [Abstract][Full Text] [Related]
31. LyGDI is a promising biomarker for ovarian cancer.
Zhen H; Yang S; Wu H; Wang S; Lv J; Ma L; Zhang X
Int J Gynecol Cancer; 2010 Apr; 20(3):316-22. PubMed ID: 20375790
[TBL] [Abstract][Full Text] [Related]
32. Immunohistological analysis of stress-induced phosphoprotein 1 in ovarian cancer patients with low serum cancer antigen 125 levels.
Chao A; Lee LY; Hsueh C; Lin CY; Tsai CL; Chao AS; Lin CT; Chou HH; Chang TC; Wang TH
Taiwan J Obstet Gynecol; 2013 Jun; 52(2):185-91. PubMed ID: 23915849
[TBL] [Abstract][Full Text] [Related]
33. Vascular endothelial growth factor (VEGF) improves the sensitivity of CA125 for differentiation of epithelial ovarian cancers from ovarian cysts.
Robati M; Ghaderi A; Mehraban M; Shafizad A; Nasrolahi H; Mohammadianpanah M
Arch Gynecol Obstet; 2013 Oct; 288(4):859-65. PubMed ID: 23564055
[TBL] [Abstract][Full Text] [Related]
34. The concomitant determination of different tumor markers in patients with epithelial ovarian cancer and benign ovarian masses: relevance for differential diagnosis.
Gadducci A; Ferdeghini M; Prontera C; Moretti L; Mariani G; Bianchi R; Fioretti P
Gynecol Oncol; 1992 Feb; 44(2):147-54. PubMed ID: 1312052
[TBL] [Abstract][Full Text] [Related]
35. Expression and clinical significance of tumor markers in ovarian mature cystic teratoma.
Chen JM; Gao HY; Wang Q; Li Q
Clin Exp Obstet Gynecol; 2016; 43(3):397-400. PubMed ID: 27328499
[TBL] [Abstract][Full Text] [Related]
36. Postoperative serum CA19-9, CEA and CA125 predicts the response to adjuvant chemoradiotherapy following radical resection in pancreatic adenocarcinoma.
Xu HX; Li S; Wu CT; Qi ZH; Wang WQ; Jin W; Gao HL; Zhang SR; Xu JZ; Liu C; Long J; Xu J; Ni QX; Yu XJ; Liu L
Pancreatology; 2018 Sep; 18(6):671-677. PubMed ID: 30153903
[TBL] [Abstract][Full Text] [Related]
37. CA125 and HE4: Measurement Tools for Ovarian Cancer.
Zhao T; Hu W
Gynecol Obstet Invest; 2016; 81(5):430-5. PubMed ID: 27160726
[TBL] [Abstract][Full Text] [Related]
38. CA72-4 combined with CEA, CA125 and CAl9-9 improves the sensitivity for the early diagnosis of gastric cancer.
Yang AP; Liu J; Lei HY; Zhang QW; Zhao L; Yang GH
Clin Chim Acta; 2014 Nov; 437():183-6. PubMed ID: 25086284
[TBL] [Abstract][Full Text] [Related]
39. Proteomic biomarkers apolipoprotein A1, truncated transthyretin and connective tissue activating protein III enhance the sensitivity of CA125 for detecting early stage epithelial ovarian cancer.
Clarke CH; Yip C; Badgwell D; Fung ET; Coombes KR; Zhang Z; Lu KH; Bast RC
Gynecol Oncol; 2011 Sep; 122(3):548-53. PubMed ID: 21708402
[TBL] [Abstract][Full Text] [Related]
40. The prognostic values of CA125, CA19.9, NSE, AND SCC for stage I NSCLC are limited.
Ma S; Shen L; Qian N; Chen K
Cancer Biomark; 2011-2012; 10(3-4):155-62. PubMed ID: 22674301
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
